Andy Yeung, Ph.D.Chief Technology Officer at Asher Biotherapeutics
Andy Yeung currently serves as the Chief Technology Officer of Asher Biotherapeutics, responsible for the engineering and development of antibody and cytokine candidates. Previously Andy was at Pfizer, leading protein engineering efforts for various programs including CD3 bispecific, CAR T, and immuno-oncology (antibodies and cytokines). Prior to Pfizer, Andy was a post-doctoral fellow in the Antibody Engineering Department at Genentech. Andy received his Ph.D. and M.S. in Chemical engineering from Massachusetts Institute of Technology, and a B.Sc. in Chemical Engineering from University of Wisconsin-Madison.